FURAZOL
Print

Description


Composition

FURAZOL Tablets:
Each tablet contains:
Metronidazole 200 mg + Diloxanide furoate 250 mg
FURAZOL Suspension:
Each 5 ml contains:
Metronidazole 200 mg + Diloxanide furoate 100 mg

Therapeutic Indications

Acute amoebic dysentery.
Acute and chronic intestinal amoebiasis.
Extra-intestinal amoebiasis; hepatic and other systemic infections due to Entamoeba histolytica.
Giardiasis.

Dosage and Administration

Adults: 2 tablets 3 times daily for 5-10 days.
Children:
Children 2-5 years: One teaspoonful (5 ml) 3 times daily for 5-10 days.
Children 5-12 years: Two teaspoonfuls (10 ml) 3 times daily for 5-10 days; or 0.5-1 tablet 3 times/day.

Contraindications

Hypersensitivity to the product.

Warnings and Precautions

Patients should be advised to complete the course, and not to drink alcoholic beverages while taking FURAZOL.
Clinical and laboratory monitoring is advised in patients receiving prolonged (> 10 days) or intensive treatment with FURAZOL.
Doses should be reduced in elderly and in patients with severe hepatic impairment.
FURAZOL should be avoided during pregnancy, especially during the first trimester.
FURAZOL should be avoided by nursing mothers or children less than 2 years of age.
Treatment of Overdose: There is no specific antidote; gastric lavage and symptomatic treatment are recommended.

Drug Interactions

When given with alcoholic beverages, FURAZOL may produce a disulfiram-like reaction with abdominal cramps, nausea, vomiting, headache, flushing and palpitations.
Metronidazole impairs the metabolism or excretion of warfarin and other oral coumarin anticoagulants; it increases blood levels of these agents, resulting in prolongation of prothrombin time.
Co-administration with drugs increasing liver enzyme activity such as phenytoin or phenobarbital, may accelerate the elimination of metronidazole resulting in reduced plasma levels, with a consequent reduction in the effectiveness of FURAZOL.
Simultaneous administration of drugs that decrease liver enzyme activity, such as cimetidine, may prolong the half-life and increase plasma concentrations of metronidazole and might increase the risk of neurological side effects.

Undesirable Effects

Occasional mild gastrointestinal disturbances, flatulence, nausea, vomiting, metallic taste, headache, ataxia, urticaria, angioedema and darkening of urine may occur.